Stalling Progress in Cancer Survival Rates in England and Wales

Recent research indicates that the substantial advancement in cancer survival rates observed since the 1970s has begun to slow in recent years. A comprehensive study conducted by the London School of Hygiene & Tropical Medicine analyzed data spanning nearly five decades, including over 10 million adults diagnosed with cancer between 1971 and 2018, with follow-up extending to 2019. The findings reveal that while overall survival for all cancers combined has significantly improved—from a 23.7% 10-year survival rate in the early 1970s to nearly 50% in 2018—this upward trajectory has decelerated over the last decade. The study notes that improvements in survival were three times faster in the early 2000s compared to the early 2010s, potentially due to increasing pressures on NHS cancer services, leading to longer delays in diagnosis and treatment.

The research emphasizes that although certain cancers like breast, bowel, and cervical have seen notable improvements due to effective screening and early detection, many others, such as lung, stomach, oesophageal, and brain cancers, remain difficult to treat, with minimal progress over the past 50 years. For example, 10-year survival rates for lung and brain cancers are below 20%, and pancreatic cancer survival remains under 5%. Consequently, disparities among cancer types have widened, with survival ranging from nearly 97% for testicular cancer to just over 4% for pancreatic cancer.

Experts highlight the importance of continuous data collection and research. Professor Michel Coleman described the Cancer Survival Index as a vital policy tool to track and set targets for NHS cancer strategies. Co-author Professor Claudia Allemani stressed that despite significant improvements, the stagnation poses risks, especially as the proportion of early-stage diagnoses remains below the government’s 2028 target of 75%. Researchers advocate for stronger efforts to enhance early detection, treatment innovations, and resource allocation.

Prominent voices such as Cancer Research UK call for comprehensive initiatives in early diagnosis and research funding to combat the slow growth in survival improvements. They warn that ongoing delays and health system pressures could hinder future progress, emphasizing the need for political and financial commitment to support cancer control efforts.